Regulus Therapeutics Inc Total Liabilities
Regulus Therapeutics Inc total liabilities. Based on the latest financial reports, Regulus Therapeutics Inc (RGLS) has total liabilities worth $5.80 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Regulus Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Regulus Therapeutics Inc (2010–2024)
Total liabilities of Regulus Therapeutics Inc from 2010 to 2024. This chart illustrates how Regulus Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Regulus Therapeutics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Regulus Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Regulus Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Diversified Royalty Corp
TO:DIV
|
Canada | CA$739.57 Million |
|
DL Holdings CO. LTD.
KO:000210
|
Korea | ₩7.16 Trillion |
|
Tifico Fiber Indonesia Tbk
JK:TFCO
|
Indonesia | Rp31.36 Million |
|
Ningbo Marine Co Ltd
SHG:600798
|
China | CN¥1.88 Billion |
|
Atom Hoteles Socimi
MC:YATO
|
Spain | €300.48 Million |
|
GSP Automotive Group Wenzhou Co Ltd
SHG:605088
|
China | CN¥3.63 Billion |
|
Beijing Hualian Department Store Co Ltd
SHE:000882
|
China | CN¥5.93 Billion |
|
Hunan Hansen Pharmaceutical Co Ltd
SHE:002412
|
China | CN¥310.49 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Regulus Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RGLS total assets.
Liquidity & Leverage Metrics
Regulus Therapeutics Inc Total Liabilities Ratios Explained
Regulus Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Regulus Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Regulus Therapeutics Inc (2010–2024)
The table below shows the annual total liabilities of Regulus Therapeutics Inc from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $7.77 Million | -18.72% |
| 2023-12-31 | $9.56 Million | -28.77% |
| 2022-12-31 | $13.43 Million | -0.53% |
| 2021-12-31 | $13.50 Million | +16.57% |
| 2020-12-31 | $11.58 Million | -47.53% |
| 2019-12-31 | $22.07 Million | -34.68% |
| 2018-12-31 | $33.78 Million | -20.69% |
| 2017-12-31 | $42.59 Million | -4.47% |
| 2016-12-31 | $44.59 Million | +162.19% |
| 2015-12-31 | $17.00 Million | -56.91% |
| 2014-12-31 | $39.47 Million | +33.30% |
| 2013-12-31 | $29.61 Million | -28.53% |
| 2012-12-31 | $41.42 Million | -50.90% |
| 2011-12-31 | $84.38 Million | +63.18% |
| 2010-12-31 | $51.71 Million | -- |
About Regulus Therapeutics Inc
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target o… Read more